'IIb or not IIb or maybe IIb?' Is that the question? Or is it 'which IIb and to whom?'

Catheterization and Cardiovascular Interventions

Volumn 51, Issue 2, 2000, Pages 145-146

  Brinker, Jeffrey A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; CREATINE KINASE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST;

ANGIOCARDIOGRAPHY; ARTERY DISSECTION; CORONARY ARTERY DILATATION; CORONARY ARTERY THROMBOSIS; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; EDITORIAL; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MORTALITY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROGNOSIS; Q WAVE;

ANTIBODIES, MONOCLONAL; CORONARY DISEASE; HUMAN; IMMUNOGLOBULINS, FAB; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; STENTS; TREATMENT OUTCOME;

EID: 0033774915     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/1522-726X(200010)51:2<145::AID-CCD3>3.0.CO;2-Z     Document Type: Editorial

References (6)

1. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
2. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
3. Randomized placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade
4. Evaluation of the role of abciximab (ReoPro) as a rescue agent during percutaneous coronary interventions: In-hospital and six month outcomes
5. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins
6. Abciximab reduces mortality in diabetics following percutaneous coronary intervention